A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combination with 2 nucleoside RTIs) in naive HIV-1 positive patients
- Conditions
- Treatment of HIV infection in naive HIV-1 positive patientsMedDRA version: 6.1Level: PTClassification code 10020162
- Registration Number
- EUCTR2004-000786-35-IT
- Lead Sponsor
- ABBOTT
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method